On January 21, 2026, BioAge Labs announced the successful pricing of an upsized underwritten public offering of 5,897,435 shares of its common stock at $19.50 per share, generating approximately $115.0 million in gross proceeds. The company also granted the underwriters a 30-day option to purchase up to an additional 884,615 shares. Joint book-running managers for the deal were Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. The offering is scheduled to close on or about January 23, 2026, subject to customary closing conditions under a registration statement on Form S-3 that became effective November 25, 2025.

BioAge intends to deploy net proceeds from the offering—together with existing cash, cash equivalents and marketable securities—to advance its lead candidate BGE-102 (an orally available NLRP3 inhibitor), further develop its APJ agonist programs for obesity, fund ongoing research and process development, scale manufacturing capacity, reduce indebtedness, and cover general corporate purposes. This infusion of capital extends the company’s runway into mid-2027, supports enrollment of additional multiple-ascending-dose cohorts in its Phase 1 BGE-102 trial, and underwrites the planned Phase 1b/2a diabetic macular edema study scheduled to initiate in mid-2026.

The offering strengthens BioAge’s balance sheet as it positions BGE-102 to deliver two pivotal data readouts: cardiovascular risk biomarker results in the second half of 2026 and proof-of-concept ophthalmology data in mid-2027. Proceeds will also accelerate long-acting injectable and oral small-molecule APJ agonist development, potentially unlocking a differentiated obesity program. Investors gain visibility on near-term catalysts across multiple indications—cardiovascular, metabolic and retinal diseases—and BioAge’s ability to execute on its proprietary human-longevity-based discovery platform.